Introducing the First Sustained Ovarian Stimulation—
IVF Therapy Leaps Forward

Proven Efficacy
- 38.9% ongoing pregnancy rate per started cycle
- Proven in the world’s largest IVF trial

Reduced Complexity
- One injection replaces 7 daily injections of conventional gonadotropin
- Two simple dosing options based on weight
- Prefilled injection device for ease and precision
- ELONVA in the GnRH antagonist protocol reduces the number of injections by 70% compared to daily gonadotropin in a long GnRH agonist protocol


MSD
Copyright © 2011 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A. All rights reserved. 05/2011 MSD-8066-0000

download by guest on 27 April 2019